KRAS and YAP1 converge to regulate EMT and tumor survival

Diane D. Shao, Wen Xue, Elsa B. Krall, Arjun Bhutkar, Federica Piccioni, Xiaoxing Wang, Anna C. Schinzel, Sabina Sood, Joseph Rosenbluh, Jong W. Kim, Yaara Zwang, Thomas M. Roberts, David E. Root, Tyler Jacks, William C. Hahn

Research output: Contribution to journalArticleResearchpeer-review

422 Citations (Scopus)


Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling. 

Original languageEnglish
Pages (from-to)171-184
Number of pages14
Issue number1
Publication statusPublished - 3 Jul 2014
Externally publishedYes

Cite this